NCT05274659View on ClinicalTrials.gov

A Study to Evaluate the Safety and Tolerability of KJ103 in Healthy Adults

PHASE1CompletedINTERVENTIONAL

Enrollment

34

Participants

Timeline

Start Date

May 19, 2022

Primary Completion Date

March 18, 2023

Study Completion Date

August 18, 2023

Conditions

Healthy

Interventions

DRUG

KJ103

Recombinant Immunoglobulin G Cleaving Enzyme

DRUG

Placebo

Placebo

Trial Locations (1)

1010

New Zealand Clinical Research, Auckland

All Listed Sponsors

lead

Shanghai Bao Pharmaceuticals Co., Ltd.

INDUSTRY